Company profile
ACADIA Pharmaceuticals Inc.
NASDAQ: ACAD · Healthcare · Biotechnology
#152 of 1,418 Healthcare companies by revenue58th-percentile growth
EA Score
82B+FH 87DQ 85GM 62SS 85
v0.1 · 65/100 weight · provisional
↑ net margin, return on assets · ↓ growth stability, revenue growth (YoY)
Methodology →Revenue TTM
$1.1B
Rev growth YoY (TTM)
+9.9%
Net income (FY)
$391.0M
Employees
798
as of 2026-08-07
Market cap
$4.9B
as of 2026-08-07
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.1B$1.1B2025
Net income$391.0M$391.0M2025
Operating income$104.8M$104.8M2025
Total assets$1.6B$1.6B2025
Liabilities$336.8M$336.8M2025
Equity$1.2B$1.2B2025
Revenue trend
FY2022 – FY2025 · USD
FY22
FY22
FY23
FY23
FY23
FY23
FY24
FY25
Revenue by segment
Filed disclosures · FY2018
By product
Product100%
By geography
Not disclosed.
The read
What is ACADIA Pharmaceuticals Inc.’s revenue?
ACADIA Pharmaceuticals Inc. booked $1.1B in FY2025 revenue, growing 12% year over year — about the middle of the pack among Healthcare companies we track, at a 36.5% net margin.
Peers · Healthcare
Waystar Holding Corp.70BPrestige Consumer Healthcare Inc.79B+Embecta Corp.67BBone Biologics Corporation45DTandem Diabetes Care, Inc.67BWELL Health Technologies Corp.71BNeighbors
San Diego →Key facts
CEOCatherine E. Owen Adams
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
ExchangeNASDAQ: ACAD
Employees798
IPO date2004-05-27
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.